Application Data Sheet 37 CFR 1.76 Attorney Docket Number
`
`43612-0002004
`
`Application Number
`
`13/870,87 L
`
`Title of Invention
`
`Antagonist Antibodies D irected Against Calcitonin Gene- Related Peptide
`
`I ~~ntinuation 113/179,846
`I
`
`I
`
`17/11/2011
`
`18,586,045
`
`111/19/2013
`
`This section allows for U1e appUcant to e iU1er claim benefit under 35 U.S.C. 119(e), 120, 12 I , or 365(c) or indicate
`National Stage entry from a PCT application. Providing thjs information in Ule application data sheet constitutes the
`specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`Wl1en refening to Ule current application, please leave the " Aoolication Number" field blank.
`I
`I
`
`Prior
`Application
`Number
`
`Filing Date
`(MM/DD/YYYY)
`
`Patent No.
`
`Issue Date
`(MM/DD/YYYY)
`
`12/093,635
`
`I 1/10/2008
`
`8,007,794
`
`8/30/2011
`
`I
`
`Prior Application Patented
`Status
`Application
`Number
`
`Continuity
`Type
`
`13/179,846
`
`Continuation
`of
`
`I
`
`This section allows for the applicant to either claim benefit under 35 U.S.C. l 19(e), 120, 121, or 365(c) or indicate
`National Stage entry from a PCT application. Providing Uris information in ilie application data sheet constitutes the
`specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to Ule current aoolication, olease leave tl1e " Aoolication Number" field blank.
`
`Prior Aoolication Status
`Aoolication Number
`
`Expired
`Continuity Type
`
`Prior Aoolication Number
`
`Filing Date (MMJDD/YYYY)
`
`12/093,635
`
`A 371 of
`International
`
`PCT/IB2006/00318 l
`
`11/2/2006
`
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate
`National Stage entry from a PCT application. Providing tllis information in the application data sheet constitutes the
`specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When rcfening to the current aoolication, olease leave Ule " Aoolication Number" field blank.
`
`Prior Aoolication Status
`Aoolication Number
`
`Expired
`Continuity Type
`
`PCT /IB2006/00318 l
`
`Claims benefit
`from provisional
`
`Prior Aoolication Number
`60/736,623
`
`Filing Date (MM/DD/YYYY)
`11/14/2005
`
`Foreign Priority Information:
`
`

`

`Application Data Sheet 37 CFR 1.76 Attorney Docket Number
`
`436 12-0002004
`
`Application Number
`
`13/870,87 L
`
`Title of Invention
`
`Antagonist Antibodies D irected Against Calcitonin Gene- Related Peptide
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data
`sheet constitutes the claim for priority as required by 35 U.S.C. I 19(b) and 37 CFR l.55(d). When priority is claimed to a
`foreign application that is e ligible for retrieval under the priority document exchange program (PDX) the information will be
`used by the Office to automatically attempt retrieval pursuant to 37 CFR l.55(h)(l) and (2). Unde r the PDX program, applicant
`bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the
`participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time
`oeriod soecified in 37 CFR l.55(g)(l).
`
`Aoolication Number
`
`Countiv
`
`Filing Date (MM/DD/YYYY)
`
`Access Code (if applicable)
`
`Statement under 37 CFR 1.55 or 1.78 for AJA (First Inventor to File) Transition
`Applications
`C]
`This application (1) claiJns priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`16, 2013.
`
`Note: By provid.ing this statement under 37 CFR 1.55 or 1.78, this application, w ith a filing date on o r after March 16, 2013,
`will be examined under U1e first inventor to file provisions of the AIA.
`
`Authorization or Opt-Out of Authorization to Permit Access:
`
`When this Application Data Sheet is properly signed and filed wiU1 the application, applicant has provided written authority to
`permit a participating foreign intellectual property (JP) office access to the instant application-as-filed (see paragraph A in
`subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see
`paragraph B in subsection I below).
`
`Should applicm1t choose not to provide an authorization identified in subsection 1 below, applicant must opt-out of the
`authorization by checking the corresponding box A or B or both in subsection 2 below.
`
`NOTE: This section o f the Application Data Sheet is ONLY reviewed and processed with the INlTIAL fil ing of an application.
`After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access
`by a foreign IP office(s). Instead, Fom1 PTO/SB/39 or PTO/SB/69 must be used as appropriate.
`
`1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Prioritv Document Exchange {PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned
`berebv grants the USPTO autboritv to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean
`Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World
`Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating wiU1 the USPTO in a
`bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant
`patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign
`or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and
`(3) the date of filing of this Authorization. See 37 CFR l.14(h)(l).
`
`

`

`Application Data Sheet 37 CFR 1.76 Attorney Docket Number
`
`43612-0002004
`
`Application Number
`
`13/870,87 L
`
`Title of Invention
`
`Antagonist Antibodies D irected Against Calcitonin Gene- Related P eptide
`
`B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the
`undersigned hereby grants the USPTO authority to provide the EPO access to the bibliographic data and search results from the
`instant patent application when a E uropean patent application claiming priority to the instant patent application is fi led. See 37
`CFR l.l4(h)(2).
`
`The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy
`of search results from the instant application without delay in a European patent application that claims priority to the instant
`application.
`
`2. Opt-Out of Authorizations to Penn it Access by a For·eign JntelJectual Pro1>crty Officc(s)
`
`U A. Applicant DOES NOT authorize the USPTO to pennit a participating foreign IP office access to the instant application(cid:173)
`as-filcd. If this box is checked, the USPTO will not be prov iding a participating foreign TP office with any documents and
`information identified in subsection 1 A above.
`
`Cl B. Applicant DOES NOT authorize the USPTO to transmit to the EPO any search results from the instant patent
`application. If this box is checked, the USPTO will not be prov iding the EPO with search results from the instant application.
`
`NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the
`application in accordance with 37 CFR 1.14.
`
`Applicant Information:
`Providing assignment irrfonnation in this section does not substilltte for compliance with any requirement of pa1t 3 of Title 37
`of CFR to have an assignment recorded by the Office.
`
`Aoulicant 1
`If the applicant is the inventor (or the re1nainingjoint inventor or inventors under 37 CFR 1.45), this section should not be
`completed. The information to be provided in this section is the name and address of the legal representative who is the
`applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to
`assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37
`CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or
`person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or
`inventors who are also the aoolicant should be identified in this section.
`!};} Assignee
`J D Legal Representative under 35 U.S.C. 117
`
`I C! Joint Inventor
`
`U Person to whom the inventor is obligated to assign.
`
`J U Person who shows sufficient proprietary interest
`
`If applicant is the legal representative, indicate the auU10rity to file the patent application, the inventor is:
`
`Name of the Deceased or Legally Incapacitated Inventor :
`
`If U1e Applicant is an Organization check here. tR!
`
`

`

`Application Data Sheet 37 CFR 1.76 Attorney Docket Number
`
`436 12-0002004
`
`Application Number
`
`13/870,87 L
`
`Title of Invention
`
`Antagonist Antibodies D irected Against Calcitonin Gene- Related Peptide
`
`Organization Name Labl)'S Biologics, Inc. Teva Pharn1aceuticals International GmbH
`
`Prefix
`
`Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`Mailin2 Address Information:
`Address 1
`l& Hl Gatewa,· t)w.·e Ra1werswil-Jona
`
`Address 2
`City
`Country
`
`Phone Number
`Email Address
`
`£Hite 2JQ
`Safi Maleo Jona
`YSCH
`e§Q ;;g9 2HlQ
`
`State/Province
`Postal Code
`
`GA
`94404 8645
`
`Fax Number
`
`e§Q §l;J le4&
`
`Assignee Information including Non-Applicant Assignee Information:
`Providing assignment infonnation in this section does not substitute for compliance with any requirement of part 3 of Title 37
`of CFR to have an assignment recorded by the Office.
`
`Assi!!Jlee l
`Complete this section if assignee in.fonnation, including non-applicant assignee inforn1ation, is desired to be included on the
`patent application publication. An assignee-applicant identified in the "Applicant Information" section ·will appear on the patent
`application publication as an applicant. For an assignee-applicant, complete this section only if identification as a11 assignee is
`also desired on the patent aoolication publication.
`
`If tlle Assignee or Non-Applicant Assignee is an Organization check here. c:1
`
`Organization Nan1e
`
`Prefix.
`
`Given Name
`
`Middle Name
`
`Family Name
`
`Suffix
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`Address 1
`Address 2
`City
`Country
`Phone Number
`En1ail Address
`
`State/Province
`Postal Code
`Fax Number
`
`Signature:
`A signature of the applicant or representative is required in accordance witl1 37 CFR 1.33 and 10.18. Please see 37 CFR l .4(d)
`for the form of the signature.
`I /Todd E. Garcia, Reg. No. 54,112/
`
`Signature
`
`I Date
`
`I 12/20/2016
`
`

`

`Application Data Sheet 37 CFR 1.76 Attorney Docket Number
`
`43612-0002004
`
`Application Number
`
`13/870,87L
`
`Title of Invention
`
`Antagonist Antibodies D irected Against Calcitonin Gene- Related Peptide
`
`First Name
`
`Todd
`
`23599105.doc
`
`j Last
`Name
`
`j Garcia
`
`(MM/DD/YYYY)
`Registration
`Number
`
`54,112
`
`